APLS241220C10000
- 53.20
- 0.000.00%
Apellis Pharmaceuticals Newsroom
Scotiabank Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $57
Apellis Pharmaceuticals (APLS) Receives a Buy From Jefferies
Piper Sandler Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $32
Piper Sandler Remains a Hold on Apellis Pharmaceuticals (APLS)
Wells Fargo Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating, Maintains Target Price $30
J.P. Morgan Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating
Hold Rating on Apellis Pharmaceuticals Amid Regulatory Setbacks and Market Uncertainties
Apellis Pharmaceuticals Is Maintained at Outperform by Baird
Apellis Pharmaceuticals Analyst Ratings
UBS Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Cuts Target Price to $45
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $55
Apellis Pharmaceuticals Price Target Cut to $30.00/Share From $43.00 by Wells Fargo
Oppenheimer Adjusts Apellis Pharmaceuticals Price Target to $40 From $65, Maintains Outperform Rating
A Quick Look at Today's Ratings for Apellis Pharmaceuticals(APLS.US), With a Forecast Between $30 to $75
Apellis Pharmaceuticals (APLS) Receives a Hold From Piper Sandler
Apellis Pharmaceuticals Is Maintained at Buy by B of A Securities
Strategic Positioning and Strong Efficacy Drive 'Buy' Rating for Apellis Pharmaceuticals
Apellis Pharmaceuticals: Hold Rating Amid Revenue Miss and Financial Challenges
Wedbush Adjusts Price Target on Apellis Pharmaceuticals to $25 From $27, Maintains Neutral Rating